Story perspectives

FDA Recalls Rheumacare Capsules Over Dangerous Lead Levels

12/24/2025

32 6

Summary

Story summary

The U.S. Food and Drug Administration announced a recall of Rheumacare joint pain capsules after testing found lead above limits.
Handelnine Global Limited, operating as Navafresh, recalled two Rheumacare lots, CAM040 and CALO79-N.
The FDA warned that prolonged lead exposure can cause cognitive impairment and motor loss.
Handelnine previously received a warning letter about unapproved drugs.
Consumers are urged to dispose of recalled product and may contact Handelnine for inquiries.

1 of 1

Story summary

The U.S. Food and Drug Administration announced a recall of Rheumacare joint pain capsules after testing found lead above limits.
Handelnine Global Limited, operating as Navafresh, recalled two Rheumacare lots, CAM040 and CALO79-N.
The FDA warned that prolonged lead exposure can cause cognitive impairment and motor loss.
Handelnine previously received a warning letter about unapproved drugs.
Consumers are urged to dispose of recalled product and may contact Handelnine for inquiries.